Polypoidal choroidal vasculopathy (PCV) is characterized by abnormal choroidal vascular networks ending in aneurysmal bulges. It mainly affects Asians and pigmented individuals. Treatment options include photodynamic therapy (PDT) and intravitreal injections of anti-VEGF drugs like bevacizumab.
A study on 24-month outcomes of PDT for PCV found improvement in most patients initially, but recurrences were common later. Visual acuity was generally preserved. Anti-VEGF injections showed promise as an alternative to PDT for patients who cannot receive it. Intravitreal bevacizumab alone or with PDT led to regression of lesions and improved vision in most patients
